Connection

WILLEM OVERWIJK to Mice

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Mice.
Connection Strength

0.719
  1. Vaccinating with Stem Cells to Stop Cancer. Trends Mol Med. 2018 06; 24(6):524-526.
    View in: PubMed
    Score: 0.035
  2. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol. 2018 05 15; 200(10):3464-3474.
    View in: PubMed
    Score: 0.035
  3. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354.
    View in: PubMed
    Score: 0.035
  4. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447.
    View in: PubMed
    Score: 0.034
  5. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249.
    View in: PubMed
    Score: 0.032
  6. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
    View in: PubMed
    Score: 0.027
  7. Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72.
    View in: PubMed
    Score: 0.024
  8. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.
    View in: PubMed
    Score: 0.020
  9. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009 Jun 15; 182(12):7398-407.
    View in: PubMed
    Score: 0.019
  10. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006 May 01; 176(9):5213-22.
    View in: PubMed
    Score: 0.015
  11. A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Front Immunol. 2024; 15:1419773.
    View in: PubMed
    Score: 0.013
  12. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80.
    View in: PubMed
    Score: 0.013
  13. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Adv. 2023 06 13; 7(11):2479-2493.
    View in: PubMed
    Score: 0.012
  14. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19.
    View in: PubMed
    Score: 0.012
  15. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol. 2022; 13:794684.
    View in: PubMed
    Score: 0.012
  16. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.011
  17. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.011
  18. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.1.
    View in: PubMed
    Score: 0.011
  19. IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
    View in: PubMed
    Score: 0.011
  20. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol. 2001 Jan; 22(1):5-7.
    View in: PubMed
    Score: 0.011
  21. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937.
    View in: PubMed
    Score: 0.010
  22. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother. 2021 Apr; 70(4):1101-1113.
    View in: PubMed
    Score: 0.010
  23. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S76-80.
    View in: PubMed
    Score: 0.010
  24. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
    View in: PubMed
    Score: 0.010
  25. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2000; 20(6):433-50.
    View in: PubMed
    Score: 0.010
  26. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2982-7.
    View in: PubMed
    Score: 0.009
  27. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
    View in: PubMed
    Score: 0.009
  28. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano. 2018 10 23; 12(10):9881-9893.
    View in: PubMed
    Score: 0.009
  29. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998 Jul 20; 188(2):277-86.
    View in: PubMed
    Score: 0.009
  30. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018 03; 159:215-228.
    View in: PubMed
    Score: 0.009
  31. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
    View in: PubMed
    Score: 0.008
  32. Absence of Grail promotes CD8+ T cell anti-tumour activity. Nat Commun. 2017 08 10; 8(1):239.
    View in: PubMed
    Score: 0.008
  33. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164.
    View in: PubMed
    Score: 0.008
  34. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017 Aug; 27(8):1034-1045.
    View in: PubMed
    Score: 0.008
  35. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997 Jun; 12(2):117-23.
    View in: PubMed
    Score: 0.008
  36. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. J Immunother. 2017 01; 40(1):11-20.
    View in: PubMed
    Score: 0.008
  37. Temporally Programmed CD8a+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep. 2016 12 06; 17(10):2503-2511.
    View in: PubMed
    Score: 0.008
  38. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.008
  39. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
    View in: PubMed
    Score: 0.007
  40. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.007
  41. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol. 2015 Feb 02; 108:20.1.1-20.1.43.
    View in: PubMed
    Score: 0.007
  42. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014 Jun; 20(6):676-81.
    View in: PubMed
    Score: 0.007
  43. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.
    View in: PubMed
    Score: 0.007
  44. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.006
  45. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
    View in: PubMed
    Score: 0.006
  46. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18.
    View in: PubMed
    Score: 0.006
  47. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012 Jun 01; 188(11):5365-76.
    View in: PubMed
    Score: 0.006
  48. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
    View in: PubMed
    Score: 0.006
  49. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011; 6(8):e22939.
    View in: PubMed
    Score: 0.005
  50. Cell-intrinsic role for IFN-a-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood. 2011 Oct 06; 118(14):3879-89.
    View in: PubMed
    Score: 0.005
  51. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
    View in: PubMed
    Score: 0.005
  52. Induction of TLR4-dependent CD8+ T cell immunity by murine ?-defensin2 fusion protein vaccines. Vaccine. 2011 Apr 18; 29(18):3476-82.
    View in: PubMed
    Score: 0.005
  53. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68.
    View in: PubMed
    Score: 0.005
  54. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.005
  55. Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. J Leukoc Biol. 2010 Jul; 88(1):69-78.
    View in: PubMed
    Score: 0.005
  56. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov 20; 31(5):787-98.
    View in: PubMed
    Score: 0.005
  57. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
    View in: PubMed
    Score: 0.005
  58. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14342-6.
    View in: PubMed
    Score: 0.004
  59. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
    View in: PubMed
    Score: 0.004
  60. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6.
    View in: PubMed
    Score: 0.004
  61. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View in: PubMed
    Score: 0.004
  62. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61.
    View in: PubMed
    Score: 0.004
  63. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005 Mar 01; 174(5):2591-601.
    View in: PubMed
    Score: 0.004
  64. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate. 2002 Nov 01; 53(3):183-91.
    View in: PubMed
    Score: 0.003
  65. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 2001 Nov 01; 61(21):7920-4.
    View in: PubMed
    Score: 0.003
  66. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001 Aug 20; 194(4):481-9.
    View in: PubMed
    Score: 0.003
  67. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res. 2000 Jun; 20(6):589-96.
    View in: PubMed
    Score: 0.003
  68. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A. 2000 May 09; 97(10):5492-7.
    View in: PubMed
    Score: 0.003
  69. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000 Apr 03; 191(7):1221-32.
    View in: PubMed
    Score: 0.002
  70. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000 Jan 15; 164(2):562-5.
    View in: PubMed
    Score: 0.002
  71. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000 Jan 15; 60(2):253-8.
    View in: PubMed
    Score: 0.002
  72. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst. 1998 Dec 16; 90(24):1881-7.
    View in: PubMed
    Score: 0.002
  73. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998 Nov 15; 161(10):5313-20.
    View in: PubMed
    Score: 0.002
  74. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3183-8.
    View in: PubMed
    Score: 0.002
  75. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 1997 Mar; 15(4):387-94.
    View in: PubMed
    Score: 0.002
  76. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997 Jan; 20(1):15-25.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.